Nona Biosciences, a worldwide pioneer of know-how innovation and antibody discovery and growth options, introduced at the moment it has entered right into a collaboration settlement with Lycia Therapeutics, a pacesetter in extracellular protein degradation.
Lycia is utilizing its proprietary lysosomal focusing on chimeras (LYTACs) platform to find and develop first-in-class therapeutics that degrade extracellular and membrane-bound proteins that drive a variety of difficult-to-treat illnesses. Via the collaboration, Lycia will leverage Nona’s proprietary Harbour Mice® HCAb absolutely human antibody transgenic mice platform to find novel antibodies for its LYTAC protein degrader therapeutics.
“We’re happy to enter into this collaboration with Lycia Therapeutics, extending our service footprint to the world of extracellular protein degradation. We imagine Lycia’s leveraging of our antibody discovery capabilities will assist speed up its efforts to advance novel protein degrader therapeutics,” stated Jingsong Wang, M.D., Ph.D., Chairman of Nona Biosciences stated.
“Our LYTACs can uniquely deal with extracellular disease-driving targets that stay difficult for current antibody and small molecule modalities. We stay up for deploying Nona Biosciences’ know-how to advance the invention of novel therapeutics for at present underserved affected person populations,” stated Steve Staben, Ph.D., Chief Scientific Officer of Lycia Therapeutics.